Actuate Therapeutics (ACTU) said Tuesday that its phase 2 trial of elraglusib with gemcitabine/nab-paclitaxel, or GnP, in metastatic pancreatic cancer met primary endpoints of one-year survival rate.
The study demonstrated a one-year survival rate of 43.6% in the elraglusib-GnP arm compared to 22.5% in the GnP control arm. Median overall survival was 9.3 months for the elraglusib combination versus 7.2 months for GnP alone, Actuate said.
Actuate said it plans to share topline data and discuss next steps, including a phase 3 registration trial, with the US Food and Drug Administration in H1 2025.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。